Search

Displaying results 4621 - 4630 of 9322 in total
  1. Drug

    D-Serine

    go.drugbank.com/drugs/DB03929
    ApprovedInvestigationalWithdrawn

    A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.

  2. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738] … NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9.

    Synonyms: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9
  3. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

  4. Drug

    TA-CIN

    go.drugbank.com/drugs/DB05809
    Investigational

    TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

    Synonyms: TA-CIN
  5. Drug

    Sulfisoxazole

    go.drugbank.com/drugs/DB00263
    ApprovedVet approved

    A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

  6. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … the RNAi response against a targeted disease causing gene.

  7. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  8. Drug

    Felypressin

    go.drugbank.com/drugs/DB00093
    Investigational

    A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two … It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth

  9. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  10. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]